ReviewThe American journal of cardiology2020
Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019.
Review in The American journal of cardiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Impact of Cardiovascular Diseases on COVID-19: A Systematic Review.Medical science monitor : international medical journal of experimental and clinical research · 2021Pooled it
- Cardiovascular Risks of COVID-19 Therapeutics: Integrated Analysis of FAERS, Electronic Health Records, and Transcriptomics.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Investigating the effects of remdesivir on corrected QT interval in patients with severe COVID-19 disease: a historical cohort study.BMC cardiovascular disorders · 2024Article
- Marine drugs as putative inhibitors against non-structural proteins of SARS-CoV-2: an in silico study.Journal of molecular modeling · 2023Article
- Pharmacometric and Electrocardiographic Evaluation of Chloroquine and Azithromycin in Healthy Volunteers.Clinical pharmacology and therapeutics · 2022Article
- The potential of remdesivir to affect function, metabolism and proliferation of cardiac and kidney cells in vitro.Archives of toxicology · 2022Article
- Potential Cardiotoxic Effects of Remdesivir on Cardiovascular System: A Literature Review.Cardiovascular toxicology · 2022Review
- Use of Drugs Associated with QT Interval Prolongation at the Hospital Level during the COVID-19 Pandemic in Colombia.International journal of vascular medicine · 2022Article
- A case report on the association between QTc prolongation and remdesivir therapy in a critically ill patient.IDCases · 2022Article
- Transcriptional Effects of Candidate COVID-19 Treatments on Cardiac Myocytes.Frontiers in cardiovascular medicine · 2022Article
- Prospect of 3D bioprinting over cardiac cell therapy and conventional tissue engineering in the treatment of COVID-19 patients with myocardial injury.Regenerative therapy · 2021Review
- COVID-19-Associated Cardiovascular Complications.Diseases (Basel, Switzerland) · 2021Review
- Molecular docking studies of some selected gallic acid derivatives against five non-structural proteins of novel coronavirus.Journal, genetic engineering & biotechnology · 2021Article
- Application of Human Induced Pluripotent Stem Cell-Derived Cellular and Organoid Models for COVID-19 Research.Frontiers in cell and developmental biology · 2021Review
- Adverse Cardiovascular Effects of Anti-COVID-19 Drugs.Frontiers in pharmacology · 2021Review
- A Comparative NLP-Based Study on the Current Trends and Future Directions in COVID-19 Research.IEEE access : practical innovations, open solutions · 2021Article
- Drug-Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy.Drugs & aging · 2020Article
- Preliminary findings from stimulated spontaneous reporting of adverse drug reactions during COVID-19 pandemic: an experience from Ghana.Ghana medical journal · 2020Article
- Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes.Antiviral research · 2020Article
- Article
Corrections and comments
- Commented on by
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (COVID-19) has become a global pandemic. It is still uncontrolled in most countries and no therapies are currently available. Various drugs are under investigation for its treatment. The disease is known to have worse outcomes in patients who have underlying cardiovascular disease. Chloroquine/hydroxychloroquine, azithromycin, remdesivir and lopinavir/ritonavir are currently being studied in trials and show some promise. Conduction disorders, heart failure, and mortality have been reported with the use of these drugs. It is important to have knowledge of potential cardiotoxic effects of these drugs before using them for COVID-19 patients for better allocation of healthcare resources and improvement in clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.